Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
FOLD Stock Chart & Stats
$14.37
-$0.18(-1.98%)
At close: 4:00 PM EST
$14.37
-$0.18(-1.98%)
Day’s Range― - ―
52-Week Range$5.51 - $14.38
Previous CloseN/A
Volume320.41K
Average Volume (3M)5.66M
Market Cap
$4.51B
Enterprise Value$4.78B
Total Cash (Recent Filing)$293.54M
Total Debt (Recent Filing)$483.32M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
May 13, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding314,000,700
10 Day Avg. Volume3,015,125
30 Day Avg. Volume5,656,550
Financial Highlights & Ratios
PEG Ratio3.17
Price to Book (P/B)16.01
Price to Sales (P/S)6.92
P/FCF Ratio147.11
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue7.53
Enterprise Value/Gross Profit8.57
Enterprise Value/Ebitda88.78
Forecast
1Y Price Target
$14.08Price Target Upside-2.02% Downside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)0.29
Revenue Forecast (FY)$748.75M
Bulls Say, Bears Say
Bulls Say
Acquisition ValuationAcquisition offer from BioMarin values the company at $14.50 per share, representing about a one-third premium to pre-announcement levels and providing a clear cash outcome for shareholders.
Commercial Performance And Balance SheetGalafold sales outperformed expectations while PomOp gains in European markets, combined with GAAP profitability and a solid cash balance, support steady revenue generation and operational stability.
Intellectual Property And ExclusivitySettlement of patent disputes and agreements limiting generic entry until 2037 remove a major legal overhang and help preserve exclusive market rights for the lead therapy.
Bears Say
Analyst Ratings And Price TargetsMultiple analysts downgraded the stock to Hold or Market Perform and lowered price targets, indicating reduced expectations for upside beyond the transaction price.
Competitive Bidding EnvironmentLimited interest from additional pharmaceutical bidders and commentary that the acquisition thesis has largely played out suggest a low probability of a competing, higher offer.
Guidance And Investor VisibilityWithholding of financial guidance during the acquisition process increases visibility risk for investors and complicates near-term valuation assessments.
Amicus News
FOLD FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest stock price was $5.51 and its highest was $14.38 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Amicus Therapeutics’s market cap is $4.51B.
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 72 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Feb 20, 2026. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.071 by -$0.061.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Overvalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is 0.03.
How many shares outstanding does Amicus Therapeutics have?
Amicus Therapeutics has 314,000,700 shares outstanding.
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of $0.01 in its last earnings report, missing expectations of $0.071. Following the earnings report the stock price went up 0.139%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Currently, no hedge funds are holding shares in FOLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amicus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$14.08 (-2.02% Downside)
$14.08 (-2.02% Downside)
Blogger Sentiment
Bullish
FOLD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 18.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.36%
12-Months-Change
Fundamentals
Return on Equity
-11.58%
Trailing 12-Months
Asset Growth
21.00%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
FOLD Company Deck
FOLD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Amicus Therapeutics highlights strong financial performance with notable revenue growth and GAAP profitability, driven by their flagship products and global market expansion. Despite some increase in costs and early-stage profitability, the company's strategic focus on expanding their product pipeline and market presence suggests a positive outlook.View all FOLD earnings summariesFOLD Stock 12 Month Forecast
Average Price Target
$14.08
▼(-2.02% Downside)
Technical Analysis
Catalyst Pharma
―
Travere Therapeutics
―
Ocular Therapeutix
―
Immunovant
―
Disc Medicine
―
Ownership Overview
1.02% Insiders
28.63% Mutual Funds
13.21% Other Institutional Investors
37.18% Public Companies and
Individual Investors